Allergan (a subsidiary of AbbVie Inc.), Galderma and Merz Pharma are Dominating in the Latin America Aesthetic Injectables Market in 2020

Latin America Aesthetic Injectables Market is expected to grow with the CAGR of 6.9% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/latin-america-aesthetic-injectables-market

Latin America aesthetic injectables market is a highly consolidated market which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.   

The major players dealing in Latin America aesthetic injectables market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition and agreement into the market. This has helped the companies to maximize the sales with enhanced product portfolio. For instance, in November 2020, Galderma launched Dysport in China. It was used in the treatment of glabellar lines. Dysport had received the approval from National Medical Products Administration from China. This product launch has helped the company to highlight their dedication towards the aesthetic market and to introduce the novel product for the welfare of patients.

Allergan (a subsidiary of AbbVie Inc.) is the dominating player in Latin America aesthetic injectables market. The other key players existing in the aesthetic injectables Galderma, Laboratoires Vivacy, HUGEL, Inc., Merz Pharma, Anika Therapeutics, Inc., SKIN TECH PHARMA GROUP, Sinclair Pharma, Prollenium Medical Technologies, ADODERM GmbH, CROMA-PHARMA GmbH, BioScience GmbH, Contura Ltd., Suneva Medical, medyglobal among others.

Latin America Aesthetic Injectables MarketAllergan (a subsidiary of AbbVie Inc.):

Allergan (a subsidiary of AbbVie Inc.) is headquartered in Dublin, Ireland and was founded in 2013. The company is engaged on developing, manufacturing and marketing the pharmaceuticals, regenerative medical, surgical and biological products and devices for patients around the world. The company is providing products under categories such as central nervous system, eye care and gastroenterology, medical aesthetics, patient assistance programs and other products among which medical aesthetics is the market focused category. The company is taking various strategic initiatives in order to expand its business in the market.

For instance,

  • In November 2020, Allergan (a subsidiary of AbbVie Inc.) had celebrated its second annual BOTOX Cosmetic Day. The Cosmetic Day is dedicated for the loyalty towards the patient and the healthcare providers who have put in the efforts to make the brand what it is today towards the aesthetic community. The company organizing the National Botox Cosmetic Day is trying to increase the product portfolio and this will engage customers to purchase Botox injectables. This will increase sales and will have a positive impact in the market growth.

The company has wide presence across North America, Asia-Pacific, Europe, Middle East and Africa and South America. The company has various subsidiaries such as ZELTIQ Aesthetics (U.S.), Actavis Group (U.S.), Kythera Biopharmaceuticals (U.S.), Tobira Therapeutics (U.S.), Bonti Inc (U.S.) among more.

Galderma:

Galderma is headquartered in La Tour-de-Peilz, Switzerland and was founded in 1981. The company focuses on skin products that help in protecting, providing nourishment and enhancing the quality of the skin. The company is providing products under categories namely prescription and aesthetics and consumer solutions out of which prescription and aesthetics is the market focused category. The company is engaged in receiving the product approvals.  

For instance,

  • In May 2020, Galderma received the FDA approval for Restylane Kysse (new hyaluronic acid filler) using XpresHAn Technology. It was designed to add fullness to the lips and smooth the wrinkles. This approval has helped the company to enhance its product portfolio.

The company has wide presence across Europe, Latin America, North America, Asia-Pacific and Middle East and Africa. The company also has various subsidiary companies such as Q-Med AB (Sweden), Galderma Laboratories L.P. (U.S.), G. Production (Canada), Q-Med International Limited (UAE) and Galderma Nordic AB (Sweden) among others.

Merz Pharma:

Merz Pharma is headquartered in Frankfurt, Germany and was founded in 1908. The company is engaged on the health of the patient and help people to live a better life along with their better looks. The company is engaged in providing products under categories such as aesthetics and neurotoxins out of which aesthetics is the market focused category. The company has initiated many strategic initiatives to expand its market.

For instance,

  • In April 2019, Merz Pharma launched a new range of products belotero, belotero revive and hyaluronic acid filler combined with glycerol. It is used in reducing roughness, redness of the skin and fine lines. Skin hydration can also be enhanced and hence improving the skin’s quality. This product launch has helped the company to enhance the range of the products therefore, increasing the product portfolio.

The company has wide presence across the U.S., Europe, Canada, Mexico, Brazil and Asia Pacific. The company has various subsidiary companies such as Merz Pharmaceuticals GmbH (Germany), Merz North America (United States), Anteis S.A (Switzerland), Merz Pharma France (France) among others.